These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22882755)

  • 1. Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment.
    Barak Y; Aizenberg D
    BMC Psychiatry; 2012 Aug; 12():108. PubMed ID: 22882755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
    Olivares JM; Rodriguez-Morales A; Diels J; Povey M; Jacobs A; Zhao Z; Lam A; Villalobos Vega JC; Cuéllar JA; de Castro FJ; Quintero CM; Martíin JF; Domínguez P; Ojeda JL; Cortés SS; Cala FI; Marín CG; Castro LM; Duaso MA; Albarracín JR; Vergara GN; Benítez AF; Cleries FM; Pérez-Brian JM; Aragón AB; Navarro JC; Biedma JA; de Pedro RB; González JF; López ME; Moreno HD; López JA; Rodríguez EO; de Hoyos CM; Sacristán MP; Martín MD; Ballesteros EM; Rodríguez PA; Menéndez LF; Rivas RS; del Pino Cuadrado P; Lauffer JC; Solano JJ; Martínez JM; Solano FG; Rodríguez PG; Rodríguez JA; Cano TR; Fortacin MD; Lobeiras JM; Sampedro JM; Bravo AP; Pellicer AF; López MD; Liste JF; Fernández MR; Losada AC; Mendez RV; Romero SA; Blanco JJ; Bonaselt IT; Mahia MC; del Valle EF; Yañez PQ; Camarasa MG; Alonso JA; Mendez GF; Feliz FD; Lamela MA; Piñero MV; Alvarado PF; Gómez IL; Martín PF; Gómez JL; López AG; Jiménez AR; Nafs AE; Barquero NC; Ortiz RF; Noguera JL; Carrasco PR; Muñoz JM; Palma MM; Hortelano CM; Bonome LS; Sevilla JS; Juan JM; Ramos JM; Muñoz JL; Guisasola JE; Vazquez LS; Guerras FC; Nebot FJ; Fernández FJ; Nicolau AL; Subirats RC; Kidias MM; Navarro VF; García BF; del Rosal FM; de Vicente Muñoz T; Ballester JA; Lieb PM; Martel AD; Bea ER; Joaquim IG; Enjuanes FB; Piñol MB; Carbonell EF; Muñoz RM; Giribets CA; Sans LA; Blanco AS; Felipe MA; Muñoz PG; Villanueva AP; Arroyo MB; Borri RC; Fallada SM; Merola MC; Rodon EP; Palmes JR; Martínez EP; Catala JM; Coca AS; Ferrandiz FP; Paya EF; Caballero GI; Bonet AF; Figueras JF; Pagador PM; Garibo MM; Camo VP; Carrillo CS; Valero CP; Rebollo FJ; García Campayo J; Sala Ayma JM; Roig MM; de Uña Mateos MA; Bertolin RG; García AM; Mazo FJ; Velasco JL; Pérez LS; Casado CJ; Barba JJ; Diaz MC; Rubio JP; Mandoli AS; Herrero AU; Martínez AR; Serrano PS; Rodríguez EN; Montesinos JS; Macia JF; Mateos Marcos AM; Soto JV; Dumont MV; Pagan JP; Martínez VB; Santiuste de Pablos M; Delgado CE; Quiles MD; López FJ; Navarro PP; Torres AM; Ingles FJ; Arias-Camison JM; Manzano JC; Peña RV; Guitarte GP; Fontecilla HB; Romero JB; Gil RS; Lozano JM; Adanez LD; Zarranz Herrera-Oria I; Jiménez JP; Vaz FC; García OS; Anton CC; Casula RR; Hernandez MC; Escabias FT; Torresano JR; Pérez-Villamil AH; Estevez L; Figuero MA; Muñoz de Morales A; Calvin JL; Criado MD; Rodríguez VM; Ambrosolio EB; Madera PM; Alfaro GP; Vidal MM; Valtuille AG; Ruiz O; Cabornero GL; Echevarria Martínez de Bujo M; Mallen MJ; Puigros JS; Martorell AL; Forteza AC; Arrebola ER; Rodríguez de la Torre M; Saiz CG; Bardolet I Casas C; Linde ER; De Arce Cordon R; Molina EM; Carazo FJ; Romero JJ; Cano DV; Dorado MS; Velazquez SC; Sánchez AJ; Leon SO; Sánchez KP; Benitez MH; Zugarramurai AI; Contreras MA; De la Varga González M; Marín PB; Robina FG; García MS; Pérez FJ; Bros PC; Gómez AC; de Dios Molina Martín J; Perera JL; Averbach MC; Perera JL; Palancares EG; Gallego de Dios MT; Rojo CF; Iglesias SS; Merino MI; Mestre NP; Urdaniz AP; Sánchez JM; Seco RG; Muñoz JF; Agut MM; Lozano ML; Herguedas FM; Pena AT; García JV; Martínez AV; Sanz Granado OS; Fernández MA; Canseco JM; López PA; Martín MA; Barrio JA; Ubago JG; Bennassar MR; Díez JM; Fleta JL; Fortes FP; López CA; Medina O; Alvarez DF; Roca JM; Valladolid GR; Tavera JA; García-Castrillon Sales JA; Llordes IB; Melgarejo CA; Cañas de la Paz F; Callol VV; García MB; García JB; Leal FJ; Corrales EC; Iglesias ES; Gómez MA; Serrano GG; Chillarón EG; Aguado FJ; Castillo JJ; González AG; Vázquez JG; Peralvarez MB; Diaz MR; Mesa MY; Artiles FJ; Chao MA; Mesa MY; del Rosario Santana P; Escudero MA; Berenguer MM; Llacer JM; Berna JA; Ortiz JB; Pardell LT; Hernández-Alvarez de Sotomayor C; Méndez MR; Garate RC; Múgica BD; González MC; Domingo JP; Navarro CS; Vera GS; Cuquerella MA; Monzo JL; Boada PC; Pérez MF; Parrado EC; Sánchez JJ; Fernández JC;
    Eur Psychiatry; 2009 Jun; 24(5):287-96. PubMed ID: 19195847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
    Taylor DM; Young CL; Mace S; Patel MX
    J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone.
    Tadger S; Baruch Y; Barak Y
    Int Psychogeriatr; 2008 Dec; 20(6):1245-50. PubMed ID: 18620626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission in schizophrenia: critical and systematic review.
    AlAqeel B; Margolese HC
    Harv Rev Psychiatry; 2012; 20(6):281-97. PubMed ID: 23216066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection.
    Mihaljevic-Peles A; Sagud M; Filipcic IS; Grosic V; Pedisic I; Emsley R
    Psychiatr Danub; 2016 Sep; 28(3):263-272. PubMed ID: 27658835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia.
    Acosta FJ; Chinea E; Hernández JL; Rodríguez F; García-Bello M; Medina G; Nieves W
    Nord J Psychiatry; 2014 Apr; 68(3):180-8. PubMed ID: 23672274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.